Strides receives USFDA approval for Lidocaine Ointment
Capital MarketStrides Pharma Science announced that its step‐down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Lidocaine Ointment USP 5% from the United States Food & Drug
Administration (US FDA). Lidocaine Ointment is a generic version of Xylocaine Ointment of AstraZeneca Pharmaceuticals LP.
According to IQVIA MAT data, the US market for Lidocaine Ointment USP 5% is approximately US$ 50 Mn. The product will be marketed by Strides Pharma Inc. in the US Market and will be launched immediately.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
